Early data have revealed the clinical activity of immune checkpoint inhibitors (ICIs), which mainly target programmed cell death protein 1(PD-1) and cytotoxic T lymphocyte-associated protein 4 (CTLA-4) in small number of metastatic BRCA patients (85, 86). This evidence concerns the gene CTLA4 and invasive breast carcinoma.